{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:23:45Z","timestamp":1785795825218,"version":"3.56.0"},"publisher-location":"New York, NY","reference-count":21,"publisher":"Springer US","isbn-type":[{"value":"9781071631744","type":"print"},{"value":"9781071631751","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3175-1_45","type":"book-chapter","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:02:13Z","timestamp":1684479733000},"page":"679-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-1661","authenticated-orcid":false,"given":"Emmanuel J.","family":"Favaloro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Vong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8237-6743","authenticated-orcid":false,"given":"Leonardo","family":"Pasalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"45_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1055\/s-0031-1281028","volume":"37","author":"EJ Favaloro","year":"2011","unstructured":"Favaloro EJ (2011) von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 37:425\u2013426. https:\/\/doi.org\/10.1055\/s-0031-1281028","journal-title":"Semin Thromb Hemost"},{"key":"45_CR2","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","volume":"4","author":"JE Sadler","year":"2006","unstructured":"Sadler JE, Budde U, Eikenboom JCJ, the Working Party on von Willebrand Disease Classification et al (2006) Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 4:2103\u20132114. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.02146.x","journal-title":"J Thromb Haemost"},{"issue":"6","key":"45_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/rth2.12392","volume":"4","author":"EJ Favaloro","year":"2020","unstructured":"Favaloro EJ (2020) Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies. Res Pract Thromb Haemost 4(6):952\u2013957. https:\/\/doi.org\/10.1002\/rth2.12392","journal-title":"Res Pract Thromb Haemost"},{"key":"45_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","volume":"14","author":"WL Nichols","year":"2008","unstructured":"Nichols WL, Hultin MB, James AH et al (2008) von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 14:171\u2013232. https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01643.x","journal-title":"Haemophilia"},{"issue":"1","key":"45_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","volume":"5","author":"PD James","year":"2021","unstructured":"James PD, Connell NT, Ameer B et al (2021) ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 5(1):280\u2013300. https:\/\/doi.org\/10.1182\/bloodadvances.2020003265","journal-title":"Blood Adv"},{"key":"45_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/MBC.0b013e328332d022","volume":"20","author":"EJ Favaloro","year":"2009","unstructured":"Favaloro EJ, Mohammed S, Koutts J (2009) Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia. Blood Coagul Fibrinolysis 20:706\u2013714. https:\/\/doi.org\/10.1097\/MBC.0b013e328332d022","journal-title":"Blood Coagul Fibrinolysis"},{"key":"45_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1309\/2D6F-RR03-8EFN-28F5","volume":"118","author":"SE Rodgers","year":"2002","unstructured":"Rodgers SE, Lerda NV, Favaloro EJ, Duncan EM, Casey GJ, Quinn DM, Hertzberg M, Lloyd JV (2002) Identification of von Willebrand\u2019s disorder type 2N (Normandy) in Australia: a cross-laboratory investigation using different methodologies. Am J Clin Pathol 118:269\u2013276. https:\/\/doi.org\/10.1309\/2D6F-RR03-8EFN-28F5","journal-title":"Am J Clin Pathol"},{"issue":"17","key":"45_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.21037\/atm.2018.09.10","volume":"6","author":"EJ Favaloro","year":"2018","unstructured":"Favaloro EJ (2018) Rare forms of von Willebrand disease. Ann Transl Med 6(17):345. https:\/\/doi.org\/10.21037\/atm.2018.09.10","journal-title":"Ann Transl Med"},{"key":"45_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2147\/JBM.S266791","volume":"12","author":"CK Colonne","year":"2021","unstructured":"Colonne CK, Reardon B, Curnow J, Favaloro EJ (2021) Why is misdiagnosis of von Willebrand disease still prevalent and how can we overcome it? A focus on clinical considerations and recommendations. J Blood Med 12:755\u2013768. https:\/\/doi.org\/10.2147\/JBM.S266791","journal-title":"J Blood Med"},{"key":"45_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/aob.2018.03.05","volume":"3","author":"EJ Favaloro","year":"2018","unstructured":"Favaloro EJ, Pasalic L, Curnow J (2018) Diagnosis and management of von Willebrand disease in Australia. Ann Blood 3:31. https:\/\/doi.org\/10.21037\/aob.2018.03.05","journal-title":"Ann Blood"},{"issue":"2","key":"45_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/s-0035-1569070","volume":"42","author":"J Curnow","year":"2016","unstructured":"Curnow J, Pasalic L, Favaloro EJ (2016) Treatment of von Willebrand disease. Semin Thromb Hemost 42(2):133\u2013146. https:\/\/doi.org\/10.1055\/s-0035-1569070","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"45_CR12","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1111\/hae.13481","volume":"24","author":"Y Brennan","year":"2018","unstructured":"Brennan Y, Favaloro EJ, Curtin J, Curnow J (2018) Management of pregnancy complications in type 2N von Willebrand disease associated to a novel mutation. Haemophilia 24(3):e148\u2013e152. https:\/\/doi.org\/10.1111\/hae.13481","journal-title":"Haemophilia"},{"issue":"1","key":"45_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","volume":"5","author":"NT Connell","year":"2021","unstructured":"Connell NT, Flood VH, Brignardello-Petersen R et al (2021) ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 5(1):301\u2013325. https:\/\/doi.org\/10.1182\/bloodadvances.2020003264","journal-title":"Blood Adv"},{"key":"45_CR14","doi-asserted-by":"publisher","unstructured":"Franchini M, Mannucci PM (2022) The more recent history of hemophilia treatment. Semin Thromb Hemost 48(8):904\u2013910. https:\/\/doi.org\/10.1055\/s-0042-1756188","DOI":"10.1055\/s-0042-1756188"},{"issue":"2","key":"45_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1055\/s-0041-1740148","volume":"48","author":"MND Di Minno","year":"2022","unstructured":"Di Minno MND, Minno AD, Calcaterra I, Cimino E, Dell\u2019Aquila F, Franchini M (2022) Enhanced half-life recombinant factor VIII concentrates for hemophilia A: final results from extension studies. Semin Thromb Hemost 48(2):253\u2013255. https:\/\/doi.org\/10.1055\/s-0041-1740148","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"45_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1055\/s-0040-1718887","volume":"47","author":"MND Di Minno","year":"2021","unstructured":"Di Minno MND, Di Minno A, Calcaterra I, Cimino E, Dell\u2019Aquila F, Franchini M (2021) Enhanced half-life recombinant factor VIII concentrates for hemophilia A: insights from pivotal and extension studies. Semin Thromb Hemost 47(1):32\u201342. https:\/\/doi.org\/10.1055\/s-0040-1718887","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"45_CR17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1365-2516.2011.02499.x","volume":"17","author":"A Veyradier","year":"2011","unstructured":"Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J (2011) Validation of the first commercial ELISA for type 2N von Willebrand\u2019s disease diagnosis. Haemophilia 17(6):944\u2013951. https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02499.x","journal-title":"Haemophilia"},{"key":"45_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/978-1-4939-7196-1_34","volume":"1646","author":"S Mohammed","year":"2017","unstructured":"Mohammed S, Favaloro EJ (2017) Laboratory testing for von Willebrand factor: factor VIII binding (for 2N VWD). Methods Mol Biol 1646:461\u2013472. https:\/\/doi.org\/10.1007\/978-1-4939-7196-1_34","journal-title":"Methods Mol Biol"},{"key":"45_CR19","doi-asserted-by":"publisher","unstructured":"Favaloro EJ, Pasalic L (2022) Laboratory diagnosis of von Willebrand Disease (VWD): geographical perspectives. Semin Thromb Hemost 48(6):750\u2013766. https:\/\/doi.org\/10.1055\/s-0042-1754331","DOI":"10.1055\/s-0042-1754331"},{"key":"45_CR20","doi-asserted-by":"publisher","unstructured":"Favaloro EJ, Dean E, Arunachalam S (2022) Evaluating performance of contemporary and historical von Willebrand Factor (VWF) assays in the laboratory identification of von Willebrand Disease (VWD): the Australasian experience. Semin Thromb Hemost 48(6):711\u2013731. https:\/\/doi.org\/10.1055\/s-0042-1753528","DOI":"10.1055\/s-0042-1753528"},{"issue":"3","key":"45_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.pathol.2021.07.001","volume":"54","author":"EJ Favaloro","year":"2022","unstructured":"Favaloro EJ, Dean E, Arunachalam S, Vong R, Mohammed S (2022) Evaluating errors in the laboratory identification of von Willebrand disease using contemporary von Willebrand factor assays. Pathology 54(3):308\u2013317. https:\/\/doi.org\/10.1016\/j.pathol.2021.07.001","journal-title":"Pathology"}],"container-title":["Methods in Molecular Biology","Hemostasis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3175-1_45","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:07:42Z","timestamp":1684480062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3175-1_45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071631744","9781071631751"],"references-count":21,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_45","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"20 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}